Our Leadership

Aspira Women's Health is dedicated to the discovery, development, and commercialization of AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. 

Executive Leadership Team

Mike Buhle

Mike Buhle

CEO

Mike Buhle joined Aspira Women’s Health in January 2025 and brings over 25 years of leadership experience in clinical and life sciences, specializing in sales, marketing, and strategic partnerships. Before Aspira, Mike held executive roles at Biovision Diagnostics, Congenica, and Danaher Corporation, where he drove market share growth, launched innovative technologies, and built high-performing teams.

Mike earned his bachelor’s degree in Business Management from Clarke University and is passionate about advancing solutions for women battling gynecologic diseases.

MicrosoftTeams-image (34)[27]

Michelle Snider

Senior Vice President, Commercial Strategy and Operations

Michelle Snider brings over 15 years of expertise in women’s healthcare and diagnostics. As Senior Vice President of Commercial Strategy and Operations at Aspira Women’s Health, she leads initiatives to drive growth and innovation in the field.

Before rejoining Aspira, Michelle was Vice President of Market Enablement/Sales Strategy at Sema4 Genomics, overseeing women’s health commercial strategy. She also held leadership roles at Sonic Reference Laboratory, Myriad, and Aspira, playing a key role in the development and launch of Ova1®.

Michelle holds a degree in International Business from The University of Texas at San Antonio and is dedicated to advancing women’s health diagnostics.

6702394db5ec2_headshots-3-700x700-20250410

Nicolette Possemato

Senior Vice President of Human Resources 

Nicolette Possemato has served as the Senior Vice President of Human Resources at Aspira Women's Health since March 2022. She brings over 15 years of experience in human resources management, with a strong background in strategic and operational Human Resource management and leadership

Prior to joining Aspira, Nicolette held senior management/executive roles at SOMOS IPA, WINFertility, OrthoConnecticut and Maplewood Communities. Earlier in her career she worked within the staffing industry at Robert Half, Onward Healthcare and had her own Human Resource consulting firm.

Nicolette holds a master’s degree in human resource management and counseling from the University of Bridgeport and a bachelor’s degree in marketing from Pace University.

1710513138411

Todd Pappas, Ph.D.

Vice President of R&D and Laboratory Operations      

Dr. Pappas brings 25 years of experience in research and product development across oncology and infectious disease. He has held key leadership roles in clinical research, regulatory affairs, and diagnostic innovation, driving advancements in biomarker data collection, machine learning integration, and point-of-care diagnostics.

Before joining Aspira Women’s Health, Dr. Pappas served as Vice President of Clinical and Regulatory Affairs at Reliant Immune Diagnostics, where he developed clinical research strategies and regulatory frameworks for software-integrated diagnostic tests. He also led clinical research initiatives at Everlywell, spearheaded breast cancer prognostics as Chief Science Officer at Delphi Diagnostics, and directed R&D efforts in biodefense and bio-surveillance at Luminex, managing over $14M in extramural grants.

Dr. Pappas has a BS in Biology from Loyola Marymount University, MS in Biology from California State University, and a PhD in Biomedical Science from the University of Texas Medical Branch.

photo1

Matt Ramey

Vice President of Business Development & National Alliances

With over 16 years of experience in laboratory diagnostics, Matt Ramey is responsible for driving strategic partnerships, commercial growth, and national alliances at Aspira Women’s Health. Before joining Aspira, Matt led business development at Sema4/GeneDx, forging key partnerships with government and private entities and expanding the company’s genetic testing portfolio. Prior to that, he managed regional sales teams at Clinical Pathology Labs, spearheaded new market penetration strategies, and secured high-value contracts with healthcare organizations.

Matt holds a Bachelor of Arts in Biology from the University of Texas at Austin and is committed to advancing diagnostic solutions that improve patient outcomes in women’s health.

Board of Directors

Jannie Herchuk
Jannie Herchuk

Jannie Herchuk retired from Deloitte & Touche LLP in 2022 where she served in various roles since 1984. Ms. Herchuk served most recently on the Deloitte LLP board of directors and led strategic initiatives and practices. As the audit partner for some of the firm’s most important healthcare and life sciences companies, Ms. Herchuk oversaw her client’s preparation of financial statements and led audit engagements for public and private companies. She was responsible for concluding on the fairness of those financial statements and the related internal controls over financial reporting.

Ms. Herchuck received her BBA in Accounting from Texas A&M University and is a licensed CPA in the state of Texas.

Cindy 800-800
Cynthia Hundorfean

Cynthia Hundorfean is an innovative and trusted executive who has worked in bold strokes to get health care right for patients, members, communities, and clinicians. She has a record of delivering explosive growth through transformational partnerships, strategic acquisitions, and organic growth strategies, all built on a foundation of unwavering commitment to high-quality, affordable care, and high-performing organizational culture.

She is a Sr. Partner of The CEO Advisory Network, a team of highly accomplished prior CEO’s and COOs of major nonprofit health systems across the US, with a passion for assisting today’s forward-looking CEO’s and senior executives in leading their organizations during these transformational times.

Recently, Cynthia served as the Chief Living Health Development Officer at Highmark Health, one of the largest integrated finance and delivery networks in the nation, and worked to better connect payers, providers, tech innovations, and community organizations to create a more proactive, personalized, and cost-effective health ecosystem across the organization’s national operations.

Previously, she served as the President and CEO of Allegheny Health Network (AHN), the health system fully owned by Highmark Health with 23,000+ employees, 2,500+ aligned physicians, 14 hospitals, and 300+ clinical locations, generating over $4B in annual revenue. After taking the helm in 2016, she orchestrated a return to profitability in 16 months, moving the system from a $32.6M in loss to a net profit of $51.1M. She led strategic cost reductions and improved profitability driven by a transformation to team-based care, consolidation of physical sites, and an aggressive move to value based models with considerable up-side risk.

Prior to AHN, Cynthia served as the Chief Administrative Officer at the world-renowned Cleveland Clinic for more than a decade. Under the Office of the Chief of Staff, she had operational and financial oversight of 23,000 employees and 25 clinical institutes at over 190 sites, while generating $5.5B in annual revenue. Cynthia was also part of the executive team that led the transition to be the first hospital system completely organized around patient needs with the formation of Institutes.

Cynthia’s leadership and impact in the industry have been recognized with dozens of awards including Modern Healthcare’s “Top 25 Women Leaders” and “100 Most Influential People”, Becker’s Hospital Review’s “Top Women Leaders”, and Pittsburgh Business Times “Outstanding CEOs and Top Executives”.

Stefanie Cavanaugh
Stefanie Cavanaugh

Stefanie Cavanaugh has been a senior financial executive for healthcare companies for over 30 years.

Ms. Cavanaugh has served as Chief Financial Officer of Giving Home Health Care, an at-home healthcare services company, since August 2022. From February 2015 to January 2022, Ms. Cavanaugh was the Chief Financial Officer of Apollo Endosurgery, Inc. (Nasdaq: APEN), a publicly traded medical technology company. She worked closely with the Board and Chief Executive Officer to develop guidance and investor communications, and raised over $170 million in debt and equity financing to support Apollo’s strategic and organizational objectives.

Ms. Cavanaugh began her career as an auditor at Ernst & Young after earning her BBA in Accounting and Finance at the University of Texas at Austin. Ms Cavanaugh is a licensed CPA in the state of Texas.

Lynn O’Connor
Lynn O’Connor Vos

Lynn O’Connor Vos is a healthcare CEO and Board Director with significant experience across product launches, global marketing, digital health, and M&A.

Ms. Vos is president of VosHealth LLC, a healthcare consultancy firm established in November 2020. Prior to that, she served as the Interim CEO of Modular Medical, Inc., a medical device company, from August 2021 to February 2022. She also served as president and CEO of the Muscular Dystrophy Association from October 2017 to November 2020. Previously, she spent almost 30 years as CEO of Greyhealth Group (and its predecessor company), where she built a global healthcare communications firm and worked on launches for clients across the pharmaceutical, biotech, surgical, and diagnostic sectors.

Lynn currently serves on the boards of OptimizeRX (Nasdaq: OPRX) and Modular Medical (Nasdaq: MDD), and is the chair of the board of Medisafe (a privately held company). She previously served on the board of nTelos (Nasdaq: NTLS), prior to the sale to Shentel, and on the boards of several WPP investment portfolio companies. She has served on audit, compensation, nominating and governance, and executive committees.

She has significant nonprofit board experience with The Jed Foundation, Multiple Myeloma Research Foundation (MMRF), Healthcare Businesswomen’s Association (HBA) and is a trustee of The Windward School and the YMCA of the City of New York. Lynn was named the Woman of the Year by the Healthcare Businesswomen’s Association in 2005. She was also a member of the Kraft Precision Medicine Accelerator at Harvard Business School, focused on innovation and improving outcomes in oncology and rare diseases. She earned a BSc in Nursing from Alfred University.

Winfred Parnell
Dr. Winfred Parnell

Dr. Winfred Parnell was appointed to the Nomination and Governance Committee in June 2023. He is a board-certified physician in obstetrics and gynecologic care bringing more than 20 years of board experience and expertise in strategic planning, governance, cultural transformation, regulatory & compliance, quality of care, and crisis management. The practice he founded cares for more than 3,500 women each year. He served as Chairman of the $2.3 billion Parkland Health and Hospital System during a period of transformation, overseeing the organization’s remediation of significant regulatory and compliance weaknesses. He serves on the board of private equity-backed SCA Pharm, one of the largest compounding pharmacies in the country. Dr. Parnell previously served as Chair of the Department of Obstetrics and Gynecology, Chair of the Department of Surgery, and President of the Medical Staff at Medical City Hospital in Dallas.

Dr. Parnell has additional experience serving on the boards of United Way of Dallas, Medical City Hospital, BBVA Compass Bank Board, Texas Healthcare Trustee, Parkland Center for Clinical Innovation, and the American Hospital Association.

In 2008, Dr. Parnell served on the Senator Obama health care Committee and was named a Delegate the Democratic National Convention. He is a graduate of Florida A&M University and received his MD from the University of Florida College of Medicine. He completed his internship and residency training at Parkland Hospital in Dallas, TX. and holds an Executive Certificate in Non-Profit Governance.

John Ragard
John Ragard

Mr. John Ragard joined the Board in July 2024 bringing over 46 years of experience as a venture capital investor, public equity buy-side analys, and portfolio manager. Mr. Ragard is currently a Senior Investment Advisor at Wayve Capital Management after having been a portfolio manager at Spouting Rock for over six years, where he co-managed a small-cap growth portfolio that outperformed the benchmark over the 5-year and since-inception periods. Prior to Spouting Rock, Mr. Ragard was a portfolio manager at Friess Associates where he outperformed the Russell 3000 Growth Index by over 400 basis points annually for over 20 years. Mr. Ragard received his Bachelor of Science in Economics cum laude from the Wharton School and is a Chartered Financial Analyst.

BOD
Ellen Beausang

Ellen Beausang leads the commercial and product franchise teams. She is responsible for driving growth for the organization through commercial sales teams as well as product marketing, training and driving overall strategy for the product franchises. Ellen brings an extensive track record of leading commercial, marketing and franchise organizations to strategically bring up best in class products, services and solutions.

As an industry veteran with over 25 years of experience, Ellen has held executive roles at leading pharmaceutical and diagnostic companies including Pfizer Pharmaceuticals, Thermo Fisher Diagnostics, and Quest Diagnostics. Ellen is passionate about building high-performing teams and best-in-class portfolios through a strong vision that always is customer-centric and focused. Prior to joining BioReference®, Ellen was the Executive Director for Oncology at Quest Diagnostics where she managed the go-to market strategy and product development.

Ellen holds a M.A. Degree from Seton Hall University and a dual B.S. in Sociology/Psychology.

Dr Jeffrey Cohen 800-800
Dr. Jeffrey Cohen

Dr. Cohen is a serial disrupter and entrepreneur in the medical and life science fields. His more than four decades as a practicing urologist with a specialty in oncology, several year tenure as President and CEO of a >500 bed quaternary hospital in a high needs community, and leadership position with one of the largest integrated health networks in the nation, have given him a 360 degree understanding of the economic, clinical, and social issues that impact the American health care system.

As a physician Dr. Cohen has developed and introduced several technologies and procedures to urology such as laser lithotripsy, fiber optic-based endoscopy, piezoelectric biplanar transrectal ultrasound and cryosurgery that have transformed the field and saved lives. He currently holds over 30 patents in the US for these novel discoveries.

As a private practice owner and hospital administrator Dr. Cohen has piloted and scaled approaches to patient management and treatment that create economies of scale and skill.

As an entrepreneur and venture capitalist he has helped technology and life science start-ups develop and market products that lead to better outcomes and save time and money for the health care system.

Dr. Cohen currently serves as CEO of one of those companies, ChemImage, where molecular imaging technology is redefining what is possible in both the biomedical and surgical fields and in threat detection systems.

He also leads Innovation for Allegheny Health Network where he was the driving force behind a joint venture with Innovation Works to create AlphaLab Health, a biotech and life sciences Accelerator based in Bellevue, PA. That venture is part of a larger program led by Dr. Cohen to breathe new life into closed core community institutions and physical assets to support community needs and drive economic growth.

Dr. Cohen understands disruption has uneven consequences and is actively working to make sure that the disruption underway in health care not only creates new value, but also uplifts the communities and individuals left in the wake of that change. His work and passion center around leading the transition from a sickness system to a true health care system to create more opportunity for everyone. This coincides with his family’s deep commitment to the economic and cultural health of his beloved City of Pittsburgh where they participate in several philanthropic organizations to support the continued progress of the region.

Jack Fraser 800-800
Jack Fraser

Jack Fraser is the co-founded and co-portfolio manager of the Seamark Capital Fund, a growth equities asset-management firm. Mr. Fraser and his partner founded Seamark 25 years ago after a successful institution investment advisory career at Friess Associates, CS First Boston, and Merrill Lynch Capital Markets.

Mr. Fraser earned his B.S. in Business Administration from Bowling Green State University and his M.B.A. in Finance from The Ohio State University.

Clinical Advisory Board

Dr. Downs
Levi S. Downs, Jr., MD, MS

Dr. Downs is Director of Gynecologic Oncology at Park Nicollet Health Services in Minneapolis, MN. Dr. Downs received his medical degree from the University of Pittsburgh School of Medicine in Pittsburgh, Pennsylvania. He did his residency in Obstetrics and Gynecology at Magee-Women’s Hospital of the University of Pittsburgh Medical Center. Dr. Downs completed a fellowship in gynecologic oncology at the University of Minnesota and has a Master of Science degree in clinical research from the University of Minnesota School of Public Health.

Prior to joining Park Nicollet, he was Professor of Obstetrics, Gynecology and Women’s Health at the University of Minnesota Medical School where he served as Division Director for Gynecologic Oncology, Women’s Cancer Program Director at the Masonic Cancer Center, and Chief Medical Officer of the University of Minnesota Medical Center and University of Minnesota Physicians.

Dr. Downs has served as principal investigator for numerous clinical trials investigating cervical cancer screening, diagnosis, treatment, and preventive approaches to HPV related diseases. As an active member of the American Society for Colposcopy and Cervical Pathology (ASCCP) he has participated in cervical cancer screening and management consensus conferences. He has served on the ASCCP Board and joined the Executive Committee in 2019 and is the current ASCCP President. Dr. Downs is also a member of the Society of Gynecologic Oncologists and has served as a member on the Board of Directors of many other professional societies. He has a commitment to service that extends beyond the medical profession. He was on the Board of Directors for College Possible and served as the inaugural chair of their National Board and he is currently on the Chairman Regional Board of Teach for America, Twin Cities.

Dr. Garg
Nisha Garg, MD, MS, FACOG

Dr. Garg is a board-certified gynecologist with advanced surgical training in Minimally Invasive Gynecologic Surgery (MIGS). She specializes in the surgical management of complex gynecologic conditions such as fibroids, endometriosis, abnormal uterine bleeding, congenital uterine anomalies, and adnexal masses. She also performs gender-affirming surgery. She is experienced in various surgical approaches including laparoscopy, robotics, vaginal surgery, and minilaparotomy.

Dr. Garg completed medical school at the University of Miami Miller School of Medicine, where she concurrently completed a Masters in Genomic Medicine. Upon graduation, she was inducted into Alpha Omega Alpha (AOA), the esteemed national medical honor society. She then went to the University of California, Irvine for OB/GYN residency, where she graduated with awards in MIGS, Gynecologic Oncology, and resident research. She then completed her fellowship in MIGS at Northwestern University in Chicago, IL. She now works as a Gynecologic Surgeon in Phoenix, AZ and serves as an Assistant Clinical Professor of Obstetrics and Gynecology at both the University of Arizona College of Medicine and at the Creighton University School of Medicine.

Dr. Garg’s clinical and research interests include endometriosis diagnostics, surgical education, transgender care, and surgical menopause.

Dr. Sea
Tamika Sea, MD, FACOG

Dr. Sea is a member of the American Congress of Obstetrics and Gynecology and is a Fellow of the American Board of Obstetrics and Gynecology, as well as the American Association of Gynecologic Laparoscopists.

Dr. Sea attended The University of Tennessee Health Science Center where she gained her Medical Doctorate. While at UTHSC, she was a founder of the Clinical Esperanza charity clinic associated with Christ Community Clinic in Memphis, where she served the underprivileged Hispanic community in the Greater Memphis Area. She also received the prestigious Charles C. Verstandig award during her matriculation. She later attended The Methodist Hospital/Christus St. Joseph Obstetrics and Gynecology Residency Program in Houston, TX, where she received numerous awards, including the American Association of Gynecologic Laparoscopists Resident of the Year. Since her return to Atlanta, she has had the privilege of serving the Greater South Atlanta area at Piedmont Henry Hospital, where she has served in several administrative roles, including Chairman of the Department of Obstetrics and Gynecology.

Dr. Sea is also a representative for the OBGYN Clinical Governance Council for the Piedmont Healthcare System. Her fields of interest include polycystic ovarian syndrome (PCOS), high-risk obstetrics, as well as utilizing laparoscopy and performing several pelvic floor reconstructive procedures.